RecruitingNCT07546188

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients, Integrating the Complete Care Pathway and an Interoperable Clinical Interface With Algorithms Paired With Explainability Tools.

Sponsor: Grand Hôpital de Charleroi

Trial Details

Condition	Lymphoma, Non-Hodgkin, Care Coordination
Intervention	Retrospective Group; Prospective Group
Status	Recruiting
Participants	210
Est. Completion	31 Dec 2027
Last Updated	22 Apr 2026

Primary Outcome

ROC-AUC

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * All patients aged 18 and over who are treated in the Haematology Department at the Grand Hôpital de Charleroi from November 2025 onwards * Treated for a lymphoma, Non Hodgkin * Capable of giving informed consent Exclusion Criteria: * All other patients who did not meet the eligibility criteria

Trial Sites

Countries

Belgium

View Registry Entry

Related Analysis

Belgian Study Tests Digital Monitoring System for Oral Therapy Adherence in Non-Hodgkin Lymphoma — Implications for Australian Practice

Belgian researchers are testing a digital system to predict medication adherence risks in non-Hodgkin lymphoma patients receiving oral therapies. The study could inform similar monitoring approaches in Australian haematology practice.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service